Table 2.
Histopathologic findings of patients with crescentic glomerulonephritis with concurrent membranous nephropathy in comparison to patients with other forms of crescentic glomerulonephritis or membranous nephropathy without crescents
| Diagnosis | Crescentic GN + MN | MPO+ crescentic GN w/ mesangial deposits | PR3+ crescentic GN w/ deposits | Pauci-immune crescentic GN | Endocarditis associated-GN | MN without crescents | PLA2R+ MN with crescents | Hydralazine-associated crescentic GN |
|---|---|---|---|---|---|---|---|---|
| n | 38 | 10 | 10 | 15 | 25 | 24 | 10 | 11 |
| Light microscopy | ||||||||
| % GGS | 27.3 (0–72) | 32.9 (0–63) | 20.2 (0–46) | 21.4 (0–54) | 25.2 (0–78) | 18.6 (0–75) | 14.1 (0–47) | 27.0 (11–53) |
| % Crescents | 40.6 (5–100) | 31.0 (6–67) | 42.5 (13–80) | 44.4 (5–89) | 20 (5–78) | N/A | 31 (13–76) | 22 (4–50) |
| Endocapillary hypercellularity | 4/38 | 0/10 | 0/10 | 0/15 | 12/25 | 2/24 | 0/10 | 1/11 |
| GBM spikes/holes | 16/38 | 0/10 | 1/10 | 0/15 | 0/25 | 16/24 | 10/10 | 0/11 |
| IF/TA - absent to mild | 15/38 | 4/10 | 2/10 | 7/15 | 18/25 | 13/24 | 5/10 | 5/11 |
| IF/TA - moderate to severe | 23/38 | 6/10 | 8/10 | 8/15 | 7/25 | 11/24 | 5/10 | 6/11 |
| Arteriosclerosis - absent to mild | 14/38 | 4/10 | 4/10 | 7/15 | 19/25 | 8/23 | 5/9 | 3/10 |
| Arteriosclerosis - moderate to severe | 24/38 | 6/10 | 6/10 | 8/15 | 6/25 | 15/23 | 4/9 | 7/10 |
| Immunofluorescence | ||||||||
| IgG | Trace (1/38),1+ (7/38), 2+ (17/38), 3+ (13/38) | 1+ (5/10), 2+ (5/10) | Trace (1/10), 1+ (2/10), 2+ (7/10) | 0/15 | Trace (1/25), 1+ (3/25), 2+ (2/25) | Trace (1/24), 1+ (1/24), 2+ (3/24), 3+ (19/24) | 2+ (1/10) 3+ (9/10) | Trace (2/11) 1+ (2/11) 2+ (4/11) |
| IgM | Trace (2/38), 1+ (6/38), 2+ (7/38), 3+ (1/38) | 1+ (4/10), 2+ (2/10) | Trace (2/10), 1+ (1/10), 2+ (2/10) | Trace (1/15) | 1+ (3/25), 2+ (6/25), 3+ (6/25) | Trace (1/24), 1+ (3/24), 2+ (5/24), 3+ (1/24) | 1+ (1/10) 2+ (1/10) | 1+ (6/11) 2+ (3/11) |
| IgA | Trace (3/38), 1+ (3/38), 2+ (3/38), 3+ (1/38) | Trace (2/10), 1+ (1/10) | 1+ (3/10) | 0/15 | Trace (1/25), 1+ (2/25) 2+ (1/25) | Trace (1/24), 1+ (1/24), 2+ (1/24), 3+ (2/24) | 1+ (2/10) 2+ (1/10) | 0/11 |
| C3 | Trace (3/38), 1+ (10/38), 2+ (13/38), 3+ (7/38) | 1+ (3/10), 2+ (5/10) | Trace (3/10) 1+ (1/10), 2+ (1/10), 3+ (1/10) | Trace (1/15) | 1+ (3/25), 2+ (11/25), 3+ (11/25) | Trace (5/24), 1+ (4/24), 2+ (5/24), 3+ (5/24) | 1+ (2/10) 2+ (1/10) 3+ (5/10) | Trace (2/11) 1+ (3/11) 2+ (4/11) 3+ (2/11) |
| C1q | Trace (1/38), 1+ (1/38), 2+ (1/38) | 2+ (1/10) | 1+ (1/10) | 0/15 | Trace (2/25), 1+ (7/25), 2+ (1/25) | 1+ (1/24), 3+ (1/24) | Trace (1/10) | Trace (1/11) |
| Electron microscopy | ||||||||
| Subepi deposits (any) | 31/33 | 1/9 | 3/9 | 0/11 | 3/24 | 23/23 | 10/10 | 2/11 |
| Subendo deposits | 3/33 | 0/9 | 0/9 | 0/11 | 1/24 | 3/23 | 0/10 | 1/11 |
| Mesangial deposits | 26/33 | 7/9 | 5/9 | 0/11 | 22/24 | 15/23 | 4/10 | 7/11 |
| Severe Foot process effacement | 16/33 | 1/9 | 5/9 | 2/11 | 9/24 | 19/23 | 9/10 | 3/11 |
GBM, glomerular basement membrane; GGS, global glomerulosclerosis; GN, glomerulonephritis; IF/TA, interstitial fibrosis and tubular atrophy; MN, membranous nephropathy; MPO, myeloperoxidase; N/A, not available; PLA2R, phospholipase A2 receptor; Subendo, subendothelial; Subepi, subepithelial.